EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Control de miopía en la actualidad. Tratamientos más utilizados.

Marta Tejera Jiménez, Carmen Bilbao Porta

Optometría Clínica y Ciencias de la Visión · 2024

DOI: 10.71413/4ex9a861 ↗
AstrattDettalji biblijografiċi

Astratt

Relevance: The purpose of this work is to identify treatments that provide the greatest benefits in myopia control, with the aim of preventing risk factors in the future, avoiding severe vision loss, and improving the patient's visual quality.Summary: The objective of this work is to conduct a literature review on different types of myopia control methods to determine the most commonly used and effective approach to date. Additionally, it will review both the basic concepts of myopia and the risk factors associated with its progression. A literature search was conducted in the PubMed database, optometric books, and the optometric and ophthalmic gazette of the College of Optometrists from articles published since 2000, selected based on inclusion and exclusion criteria. A total of 4939 results were found for the main objective of the work, which were narrowed down using inclusion and exclusion criteria to obtain a total of 30 articles divided into the introduction and discussion sections of the paper. Currently, treatments with significant efficacy are atropine and orthokeratology. However, there are new advancements such as peripheral defocus contact lenses that demonstrate improvements in the side effects of these two former treatments. Despite significant progress and the emergence of new treatments, further research on myopia control is necessary.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →